NMD Pharma

Investment area

Seed Investments



Date of investment

May 2016

NMD Pharma is developing novel treatments for Neuromuscular diseases such as Myasthenia gravis and ALS. The company is in preclinical development.

Visit site


Morten Graugaard Døssing


Department: Seed Investments

Morten joined Novo Holdings in 2016 and serves as Partner in the company creation team of Seed Investments where he leads new company formation. He serves on the Board of Acesion Pharma, Avilex, Camels IDS, Hoba Therapeutics, NMD Pharma, STipe Therapeutics, and Syndesi Therapeutics.

Prior to joining Novo, Morten was Director of Corporate Development at H. Lundbeck A/S where he was involved in M&A, corporate strategy, BD&L, portfolio management and equity investments. While at Lundbeck Morten successfully led the acquisition of orphan neurology company Chelsea Therapeutics for 658 USD m and was involved in a range of other deals including the 1.8 USD Bn alliance with Otsuka Pharmaceuticals as well as equity investments and spinouts. Before Lundbeck, Morten worked as commercial manager in technology transfer to commercialize and establish new companies in biotech. Earlier in his career, Morten co-led the life science consulting practice at a boutique advisory firm in Copenhagen focusing on business development and management consulting.

Morten holds an MSc in Human Biology from the University of Copenhagen.


João Ribas


Department: Seed Investments

João Ribas joined Seed Investments in 2018, focusing on early-stage investments and venture creation. He currently holds several board positions and has led investments in companies like Asgard Therapeutics, Tribune Therapeutics, and Orbis Medicines. João often combines his investment role with interim operational responsibilities in portfolio companies.

Prior to Novo Holdings, he was a Fellow at M Ventures (corporate VC of Merck KGaA), involved in the entire investment process including deal sourcing, investment selection, and due diligence. Before this, João founded new ventures in the U.S. and Europe, earning several entrepreneurial awards. During his Ph.D., he was part of MIT Hacking Medicine and led a non-profit organization in the U.S.

João earned his Ph.D. from the University of Coimbra, conducting research at Harvard Medical School and Brigham and Women’s Hospital. He regularly creates content on biotech innovation, venture creation, and entrepreneurship.